Sector pending / Biological Products, Except Diagnostic SubstancesUpdated 2026-05-10 22:07 UTC

FRA/22Z stock hub

FRA/22Z has a live ticker hub with the latest available market, valuation, profitability, growth, ownership, and risk indicators.

Browse stocks

FRA/22Zis not in this month’s coverageGet our monthly research letter — no spam

Fair value midpoint

n/a

Fair value pending

Upside to midpoint

n/a

Based on latest report

Confidence

n/a

Data quality and model convergence

Market cap

3.2B

Frankfurt Stock Exchange

Market data

Live price

Current market quote for this ticker.

Current price

FRA/22Z

In the news

Latest news · FRA/22Z

Recent company headlines from major financial publishers.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector context

Where the current metrics sit

Percentiles come from the backend screener cohort cache for the ticker's country and sector.

Forward P/E23.7

P25 n/aP50 n/aP75 n/a

Trailing P/E3.8

P25 n/aP50 n/aP75 n/a

ROE56.2

P25 n/aP50 n/aP75 n/a

ROIC2,303.7

P25 n/aP50 n/aP75 n/a

Benchmarks - 1M

S&P 500n/a

Nasdaq Compositen/a

Dow Jones Industrial Averagen/a

Russell 2000n/a

Indicator catalog

All FRA/22Z market and fundamental indicators

A searchable catalog of the available market, valuation, profitability, growth, balance-sheet, ownership, and analyst metrics for this ticker.

Available fields

189

Groups with data

Currency

DKK

Showing 189 of 189 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Country	Denmark
Country code	DE
Employees	491
Employees Change	146%
Employees Change Percent	41.13
Enterprise value	EUR 1.3B
Exchange	Frankfurt Stock Exchange
Financial currency	DKK
First seen	2026-05-10
Industry	Biological Products, Except Diagnostic Substances
Last refreshed	2026-05-10
Market cap	EUR 3.2B
Price	EUR 43.42
Price currency	EUR
Rev Per Employee	2,272,806.28x
Sic	2836
Symbol	fra/22Z
Website	https://www.zealandpharma.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings Yield	26.52%
EV Earnings	1.57x
EV/EBIT	1.48x
EV/EBITDA	1.48x
EV/FCF	1.59x
EV/Sales	1.09x
FCF yield	26.22%
Forward P/E	23.7x
P/B ratio	1.67x
P/E ratio	3.77x
P/S ratio	2.61x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT Margin	73.41%
EBITDA Margin	73.58%
FCF margin	68.43%
Gross margin	99.99%
Gross Profit	EUR 1.2B
Gross Profit Growth	17,558.95%
Gross Profit Growth Q	325%
Gross Profit Growth3 Y	342.48%
Gross Profit Growth5 Y	104.87%
Net Income	EUR 855.8M
Pretax Margin	75.13%
Profit Margin	69.21%
Profit Per Employee	EUR 1.6M
ROA	34.72
Roa5y	-10.72
ROCE	45.54
ROE	56.16
Roe5y	-41.05
ROIC	2,303.7
Roic5y	-24.85

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
Cagr10y	10.4%
Cagr15y	10.92%
Cagr1y	-28.79%
Cagr3y	13.24%
Cagr5y	11.36%
Revenue Growth	16,519.65x
Revenue Growth Q	325x
Revenue Growth3 Y	342.49x
Revenue Growth5 Y	92.83x

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Asset Turnover	EUR 0.76
Assets	EUR 2B
Cash	EUR 1.9B
Current Assets	EUR 2B
Current Liabilities	EUR 54M
Debt	EUR 55.4M
Debt EBITDA	EUR 0.06
Debt Equity	EUR 0.03
Debt FCF	EUR 0.07
Equity	EUR 1.9B
Interest Coverage	260.3
Liabilities	EUR 111.3M
Long Term Assets	EUR 38.7M
Long Term Liabilities	EUR 57.3M
Net Cash	EUR 1.9B
Net Cash By Market Cap	EUR 58.28
Net Cash Growth	72.45%
Net Debt EBITDA	EUR -2.07
Net Debt Equity	EUR -0.97
Net Debt FCF	EUR -2.22
Tangible Book Value	EUR 1.9B
Tangible Book Value Per Share	EUR 27.32

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current ratio	37.17
Net Working Capital	EUR 23.4M
Quick ratio	36.4
Working Capital	EUR 2B
Working Capital Turnover	EUR 0.11

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback Yield	-4.13%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
10Y total return	168.97%
1Y total return	-28.77%
200-day SMA	54.45
3Y total return	45.22%
50-day SMA	40.35
50-day SMA vs 200-day SMA	50under200
5Y total return	71.22%
All Time High	130.4
All Time High Change	-66.7%
All Time High Date	2024-07-10
All Time Low	5.15
All Time Low Change	742.94%
All Time Low Date	2011-11-23
ATR	1.83
Ch YTD	-32.18
High	45.12
High52	73.8
High52 Date	2025-11-20
High52ch	-41.17%
Low	43.42
Low52	31.5
Low52 Date	2026-03-09
Low52ch	37.84%
Ma50ch	7.62%
Price vs 200-day SMA	-20.26%
RSI	56.21
RSI Monthly	39.24
RSI Weekly	42.44
Sharpe ratio	-0.06x
Sortino ratio	-0
Total Return	-4.13%
Tr YTD	-32.18
Tr15y	373.04%
Tr1m	7.29%
Tr1w	9.62%
Tr3m	-18.99%

Analyst estimates

Ratings, targets, revisions, and forward estimate fields.

Metric	Value
Operating Income	EUR 907.7M
Operating margin	73.41

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	56,743,573%
Net Borrowing	-3,365,153.6
Shares Insiders	0.42%
Shares Institutions	33.42%
Shares Qo Q	0.36%
Shares Yo Y	4.13%

Other indicators

Additional ticker metrics that do not fit the primary research groupings yet.

Metric	Value
Adjusted FCF	EUR 829.4M
Average Volume	148x
Bv Per Share	27.4
CAPEX	EUR -5M
Ch10y	169
Ch15y	373
Ch1m	7.29
Ch1w	9.62
Ch1y	-28.77
Ch3m	-18.99
Ch3y	45.22
Ch5y	71.22
Ch6m	-23.15
Change	-5.79%
Change From Open	-3.77
Close	46.09
Days Gap	-2.1
Depreciation Amortization	1,999,004.5
Dollar Volume	26,095.4
Earnings Date	2026-05-07
EBIT	EUR 907.7M
EBITDA	EUR 909.7M
EPS	EUR 11.96
F Score	6
FCF	EUR 846.1M
FCF EV Yield	62.89x
Financing CF	-51,536,499
Fiscal Year End	December
Founded	1,997
Graham Number	82.16571
Graham Upside	89.23
Income Tax	EUR 73.2M
Investing CF	-390,623,442
Is Primary Listing	0
Last Earnings Date	2026-05-07
Last Report Date	2026-03-31
Ma150	54.59
Ma150ch	-20.47%
Ma20	41.1
Ma20ch	5.63%
Net CF	411,094,771
Next Earnings Date	2026-08-13
Open	45.12
P FCF Ratio	3.81
P OCF Ratio	3.79
Position In Range	0
Ppne	21,933,279.9
Price Date	2026-05-08
Price EBITDA	EUR 3.55
Ptbv Ratio	1.67
Relative Volume	4.06x
Revenue	1,236,406,618x
SBC By Revenue	1.35x
Share Based Comp	16,710,006
Tax By Revenue	5.92x
Tax Rate	7.88%
Tr6m	-23.15%
Volume	601
Z Score	24.53

Fast facts

Decision checkpoints

A compact product layer over the same report payload.

Risk gate

n/a

Named kill scenarios are reviewed before any bullish rating can stand.

Moat score

n/a

Business quality stays separate from stock attractiveness.

Forward P/E

n/a

Valuation uses the full report model stack, not a single multiple.

Next action

Research pending

Final action steps are kept in the recommendation tab.

Income

Does FRA/22Z pay a dividend?

Capital-return profile for this ticker.

Performance

FRA/22Z stock returns vs the market

Total return (incl. dividends) compared to S&P 500.

Ownership

Who owns FRA/22Z?

Insider, institutional, and short-interest positioning.

Institutional ownership

+33.4%

Share of float held by funds and institutions

Insider ownership

+0.4%

Stake held by company insiders. Higher generally signals alignment.

Short interest

n/a

Float sold short by bearish positioning

Y/Y dilution

+4.1%

Negative means the company is buying back shares.

Technical

FRA/22Z momentum and risk profile

RSI, moving-average stack, beta, and risk-adjusted return.

RSI (14)

56.2

Neutral momentum band

Price vs 200-day MA

-20.3%

50/200-day relationship not available

Beta (5Y)

n/a

Sensitivity to the broader market

Sharpe ratio

-0.06

Risk-adjusted return — higher is better; >1.0 is solid.

Questions

About FRA/22Z

Hub-level FAQ points readers to the deeper analysis pages.

What is the current fra/22Z stock rating?

fra/22Z is currently shown with the latest rating in the latest report. The hub links directly to the full analysis surface where the rating, fair-value bridge, risks, and scorecard are documented together.

Where can I read the full fra/22Z analysis?

The full report lives at /stocks/fra/22Z/analysis. The bare ticker page is a product hub that summarizes the latest read and sends readers into the relocated analysis tabs without making the analysis surface depend on the hub.

What fair-value range is used for fra/22Z?

The latest report frames fra/22Z around the latest fair-value range. Treat that range as the entry point, then check the valuation, sensitivity, and bear-case tabs before making an investment decision.

How often is the fra/22Z page updated?

The hub updates with the latest published stock report and live backend market data. The analysis pages remain reachable under /analysis, so a hub rollback does not remove the report reader.